IMM20059 / Immunome - LARVOL DELTA

IMM20059, a novel anti-EPN1 antibody, in combination with Atezolizumab significantly enhances tumor regression in the B16.F10 syngeneic melanoma model compared to anti-PD-L1 monotherapy (SITC 2022) - "Conclusions This study suggests that EPN1 is a promising tumor target. Combination treatment of IMM20059 and anti-PD-L1 could enhance the efficacy of anti-PD-L1 therapy by boosting intratumoral chemokines and attracting immune cells to the immunologically cold tumor microenvironment."

Combination therapy • IO biomarker • Monotherapy • Genito-urinary Cancer • Melanoma • Oncology • Prostate Cancer • Solid Tumor • CCL4

Immunome Presents Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting (Businesswire) - "Immunome...announced that it is presenting a poster at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting in Boston, Massachusetts highlighting the Company’s preclinical data of IMM20059, a novel anti-epsin 1(EPN1) antibody....IMM20059, Immunome’s epsin 1 (EPN1)-specific antibody, binds to the surface of multiple tumor cell lines, including lung, breast and prostate cancers in preclinical testing....Combinatorial effect (> 50% reduction in tumor volume) was demonstrated with IMM20059 and anti-PD-L1 treatment atezolizumab."

Preclinical • Breast Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor